

Revcovi™ (elapegademase-lvlr) – New orphan drug approval

- On October 5, 2018, [Leadiant Biosciences](#) announced the FDA approval of [Revcovi \(elapegademase-lvlr\)](#) for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.
- ADA-SCID is an ultra-rare, inherited genetic disorder, caused by a deficiency in the ADA enzyme that is fatal if left untreated. Patients affected by ADA-SCID have compromised immune systems that leave them unprotected from infection-producing bacteria, viruses, and fungi. ADA-SCID is estimated to occur in approximately one in 200,000 to one in 1,000,000 newborns around the world.
- ADA-SCID primarily affects infants and young children and is typically diagnosed within the first few months of life. SCID newborn screening in most states has allowed detection of ADA-SCID in newborns and has led to early initiation of ADA enzyme therapy and improved outcomes.
- Revcovi is a PEGylated recombinant adenosine deaminase (rADA) enzyme that works by supplementing levels of an essential enzyme called ADA. The recombinant technology eliminates the need to source the enzyme from animals.
 - [Adagen® \(pegademase bovine\)](#) is an enzyme replacement therapy also approved for the treatment ADA-SCID. However, the ADA used in the manufacture of Adagen is derived from bovine intestine.
- The safety and efficacy of Revcovi is based on data from two open-label clinical studies of a total of ten patients with ADA-SCID. The study endpoints evaluated ADA activity, levels of toxic metabolites that are the hallmark of ADA-SCID, and changes in lymphocyte counts.
 - Overall, results demonstrated that Revcovi increases ADA activity, reduces concentrations of toxic metabolites and improves total lymphocyte counts.
- Warnings and precautions of Revcovi include injection site bleeding in patients with thrombocytopenia and delay in improvement of immune function.
- The most common adverse reactions reported with Revcovi use were cough (50%) and vomiting (33%).
- The recommended starting dose of Revcovi is determined by whether or not the patient has had prior treatment with Adagen.
 - Transitioning from Adagen to Revcovi: 0.2 mg/kg weekly, intramuscularly (dose may also be calculated using a conversion formula provided in the drug label).
 - Adagen-naïve patients: 0.4 mg/kg weekly based on ideal body weight, divided into two doses (0.2 mg/kg twice a week), intramuscularly.
 - Refer to the Revcovi drug label for complete dosing instructions and therapeutic monitoring information.

- Leadiant Biosciences' launch plans for Revcovi are pending. Revcovi will be available as a 2.4 mg/1.5 mL (1.6 mg/mL) single dose vial.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.